Featured Publications
Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial
Ontaneda D, Sati P, Raza P, Kilbane M, Gombos E, Alvarez E, Azevedo C, Calabresi P, Cohen JA, Freeman L, Henry RG, Longbrake EE, Mitra N, Illenberger N, Schindler M, Moreno-Dominguez D, Ramos M, Mowry E, Oh J, Rodrigues P, Chahin S, Kaisey M, Waubant E, Cutter G, Shinohara R, Reich DS, Solomon A, Sicotte NL, Cooperative N. Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. NeuroImage Clinical 2021, 32: 102834. PMID: 34592690, PMCID: PMC8482479, DOI: 10.1016/j.nicl.2021.102834.Peer-Reviewed Original ResearchConceptsCentral vein signDiagnosis of MSMultiple sclerosisDiagnostic biomarkersMcDonald criteriaVein signProspective multicenter trialCross-sectional studyNumerous cross-sectional studiesNorth American ImagingNeuroradiologist reviewMulticenter trialAtypical presentationMulticenter studyTypical presentationSectional studyStudy protocolClinical careMS lesionsCentral readersEcho-planar MRIDiagnostic criteriaMS misdiagnosisMRI biomarkersMajor causeMyelin Oligodendrocyte Glycoprotein–Associated Disorders
Longbrake E. Myelin Oligodendrocyte Glycoprotein–Associated Disorders. CONTINUUM Lifelong Learning In Neurology 2022, 28: 1171-1193. PMID: 35938661, PMCID: PMC9523511, DOI: 10.1212/con.0000000000001127.Peer-Reviewed Original ResearchConceptsAcute disseminated encephalomyelitisClinical spectrumCentral nervous system autoimmune diseaseNatural historyFuture therapeutic trialsLarge cohort studyRecent case reportsDistinct clinical phenotypesDisseminated encephalomyelitisGlycoprotein autoantibodiesOptic neuritisCohort studyMost patientsRelapse patternsNeuromyelitis opticaTherapeutic trialsMultiple sclerosisAutoimmune diseasesCNS diseaseCase reportCNS diseasesAccurate diagnosisClinical phenotypeDiseaseDisordersConsensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology
Hua LH, Obeidat AZ, Amezcua L, Cohen JA, Costello K, Dunn J, Gelfand JM, Goldman MD, Hopkins S, Jeffery D, Krieger S, Newsome SD, Shah S, Sicotte NL, Yadav V, Longbrake EE. Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Neurology Clinical Practice 2021, 11: 352-357. PMID: 34484933, PMCID: PMC8382436, DOI: 10.1212/cpj.0000000000001040.Peer-Reviewed Original ResearchMultiple sclerosisNeuroimmunologic disordersFellowship trainingNeuroimmune disordersTherapeutic optionsMore subspecialistsSubspecialty workforceSclerosisFellowship curriculumDisordersConsensus curriculumFellowship programsFuture training programsTraining programPatientsNeuroimmunologySubspecialistsCare
2024
Multicenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis
Chen L, Ren Z, Clark K, Lou C, Liu F, Cao Q, Manning A, Martin M, Luskin E, O'Donnell C, Azevedo C, Calabresi P, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Bilello M, Song J, Kaisey M, Sicotte N, Reich D, Solomon A, Ontaneda D, Sati P, Absinta M, Schindler M, Shinohara R, Cooperative T. Multicenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis. Journal Of Neuroimaging 2024 PMID: 39410780, DOI: 10.1111/jon.13242.Peer-Reviewed Original ResearchParamagnetic rim lesionsArea under the curveRim lesionsMultiple sclerosisPrognosis of MSBiomarkers of chronic inflammationWhite matter lesionsMulticenter settingMulticenter studyMulticenter validationChronic inflammationBrain MRIClinical trialsIdentified lesionsMulticenterMS diagnosisLesionsParamagnetic rimAutomated segmentation methodMRIMRI biomarkersMulticenter datasetDiagnosisSclerosisTeam of trained ratersMulticenter automated central vein sign detection performs as well as manual assessment for the diagnosis of multiple sclerosis.
Manning A, Letchuman V, Martin M, Gombos E, Roberts-Fitzgerald T, Cao Q, Raza P, O'Donnell C, Renner B, Daboul L, Rodrigues P, Ramos M, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Samudralwar R, Suthiphosuwan S, Schindler M, Bilello M, Song J, Sotirchos E, Sicotte N, Al-Louzi O, Solomon A, Reich D, Ontaneda D, Sati P, Shinohara R. Multicenter automated central vein sign detection performs as well as manual assessment for the diagnosis of multiple sclerosis. American Journal Of Neuroradiology 2024 PMID: 39332906, DOI: 10.3174/ajnr.a8510.Peer-Reviewed Original ResearchCentral vein signCVS+ lesionsWhite matter lesionsMultiple sclerosisMulticenter studyProportions of white matter lesionsSuspicion of MSReceiver-operating characteristic curveFluid-attenuated inversion recoveryDiagnosis of multiple sclerosisDiagnosis of MSMagnetic resonance imagingAtypical clinical syndromeRadiological mimicsClinical syndromeDiagnostic imaging biomarkersManual assessmentT MRIClinical implementationImaging biomarkersLesionsInversion recoveryResonance imagingCharacteristic curveInter-rater reliabilityDiagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis
Toljan K, Daboul L, Raza P, Martin M, Cao Q, O’Donnell C, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis. Multiple Sclerosis Journal 2024, 30: 1268-1277. PMID: 39234802, PMCID: PMC11421977, DOI: 10.1177/13524585241271988.Peer-Reviewed Original ResearchConceptsCentral vein signPositive predictive valueOligoclonal bandsDiagnostic performanceMS diagnosisCerebrospinal fluidMultiple sclerosisPredictive valueNegative predictive valueCerebrospinal fluid testingRadiological suspicionDiagnostic accuracyImaging biomarkersDiagnosisDiagnostic biomarkersMonthsSclerosisBiomarkersPilot studyBaselineSelection 3Meta-analysis identifies common gut microbiota associated with multiple sclerosis
Lin Q, Dorsett Y, Mirza A, Tremlett H, Piccio L, Longbrake E, Choileain S, Hafler D, Cox L, Weiner H, Yamamura T, Chen K, Wu Y, Zhou Y. Meta-analysis identifies common gut microbiota associated with multiple sclerosis. Genome Medicine 2024, 16: 94. PMID: 39085949, PMCID: PMC11293023, DOI: 10.1186/s13073-024-01364-x.Peer-Reviewed Original ResearchConceptsRRNA gene sequence dataGroups of microbial taxaGene sequence dataMicrobiome community structureAbundance of FaecalibacteriumAbundance of PrevotellaAbundance of ActinomycesSequence dataBeta diversityMicrobial taxaGut microbiotaMicrobial compositionCommunity structureNetwork analysisGutBacterial correlationsMicrobiotaAbundanceMultiple sclerosisDiverse groupMeta-analysisDiversityTaxaFaecalibacteriumConclusionsOur meta-analysisShifting our attention earlier in the multiple sclerosis disease course
Epstein S, Longbrake E. Shifting our attention earlier in the multiple sclerosis disease course. Current Opinion In Neurology 2024, 37: 212-219. PMID: 38546031, DOI: 10.1097/wco.0000000000001268.Peer-Reviewed Original ResearchConceptsRadiologically isolated syndromeDisease courseStages of MSPrompt initiation of therapyDiagnostic criteriaInitiation of therapyMultiple sclerosisHigh-risk patientsClinical diseaseDisease modifying therapy useMS disease courseRandomized controlled trialsImmunomodulatory therapyPrompt initiationClinical outcomesTherapy useDiagnosed patientsMultiple sclerosis disease courseClinical MSHigh riskPatientsControlled trialsPrevent onsetDisease biologyTherapyChoroid plexus volume differentiates MS from its mimics
Levit E, Ren Z, Gonzenbach V, Azevedo C, Calabresi P, Cree B, Freeman L, Longbrake E, Oh J, Schindler M, Sicotte N, Reich D, Ontaneda D, Sati P, Cao Q, Shinohara R, Solomon A. Choroid plexus volume differentiates MS from its mimics. Multiple Sclerosis Journal 2024, 30: 1072-1076. PMID: 38481081, PMCID: PMC11288781, DOI: 10.1177/13524585241238094.Peer-Reviewed Original ResearchEmerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis
Cross A, Gelfand J, Thebault S, Bennett J, von Büdingen H, Cameron B, Carruthers R, Edwards K, Fallis R, Gerstein R, Giacomini P, Greenberg B, Hafler D, Ionete C, Kaunzner U, Kodama L, Lock C, Longbrake E, Musch B, Pardo G, Piehl F, Weber M, Yuen S, Ziemssen T, Bose G, Freedman M, Anania V, Ramesh A, Winger R, Jia X, Herman A, Harp C, Bar-Or A. Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis. JAMA Neurology 2024, 81: 373-383. PMID: 38466277, PMCID: PMC10928543, DOI: 10.1001/jamaneurol.2024.0017.Peer-Reviewed Original ResearchPrimary progressive MSGlial fibrillary acidic proteinNeurofilament heavy chainRelapsing MSCerebrospinal fluidTest cohortMultiple sclerosisDisease-modifying MS therapyMulticenter study of patientsBiomarkers of disease activityAnti-CD20 treatmentCentral nervous system biologyClinical follow-upConfirmation cohortT2 lesion volumeStudy of patientsHeavy chainCSF-GFAP levelsMS disease progressionMagnetic resonance imaging measuresNeurofilament light chainActivated glial markersStudy assessed dataFibrillary acidic proteinAnti-CD20Impact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control Study
Riley C, Venkatesh S, Dhand A, Doshi N, Kavak K, Levit E, Perrone C, Weinstock-Guttman B, Longbrake E, De Jager P, Xia Z. Impact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control Study. JMIR Public Health And Surveillance 2024, 10: e45429. PMID: 38319703, PMCID: PMC10879979, DOI: 10.2196/45429.Peer-Reviewed Original Research
2023
A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis
Daboul L, O’Donnell C, Amin M, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Prchkovska V, Raza P, Ramos M, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis. Multiple Sclerosis Journal 2023, 30: 25-34. PMID: 38088067, PMCID: PMC11037932, DOI: 10.1177/13524585231214360.Peer-Reviewed Original ResearchConceptsCentral vein signMultiple sclerosisPositive lesionsInter-rater agreementDiagnosis of MSMagnetic resonance imaging (MRI) biomarkersDiagnostic performancePossible multiple sclerosisInter-rater reliability assessmentGood diagnostic performanceMcDonald criteriaMulticenter studyVein assessmentMean ageVein signImaging biomarkersLesionsMRI sequencesCharacteristic curveSclerosisPatientsDiagnosisAssessmentParticipantsOptimal methodSecondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
Alvarez E, Longbrake E, Rammohan K, Stankiewicz J, Hersh C. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Multiple Sclerosis And Related Disorders 2023, 79: 105009. PMID: 37783194, DOI: 10.1016/j.msard.2023.105009.Peer-Reviewed Original ResearchConceptsRisk of infectionCD20 therapySecondary hypogammaglobulinemiaMultiple sclerosisAnti-CD20 therapySerum immunoglobulin levelsB cell levelsDisease managementImmunoglobulin levelsSerious infectionsTherapy clinical trialsPotential complicationsClinical trialsHypogammaglobulinemiaPatientsTreatment approachesTherapyInfectionSclerosisRiskPossible mechanismMedicationsBest practice approachComplicationsPathogenesisAnti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
Anderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R, Ciplea A, Cooper J, Fabian M, Hale T, Jacobs D, Kakara M, Krysko K, Longbrake E, Marcus J, Repovic P, Riley C, Romeo A, Rutatangwa A, West T, Hellwig K, LaHue S, Bove R. Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Annals Of Clinical And Translational Neurology 2023, 10: 2053-2064. PMID: 37675826, PMCID: PMC10647007, DOI: 10.1002/acn3.51893.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderDisease-modifying therapiesMultiple sclerosisAnti-CD20 monoclonal antibody therapyCD20 IgG1 monoclonal antibodyInfant development outcomesPatient questionnaire responsesRelative infant doseOptica spectrum disorderMonoclonal antibody therapyIgG1 monoclonal antibodyMature breastmilkClinical relapseDisease activityInfant doseMAb therapyInfant outcomesAntibody therapyPostpartum womenPostpartum periodMedical recordsInfant growthPostpartum treatmentNeurological conditionsBreastmilkEarly Treatment for Multiple Sclerosis
Longbrake E, Kalincik T. Early Treatment for Multiple Sclerosis. Neurology 2023, 101: 549-550. PMID: 37468283, DOI: 10.1212/wnl.0000000000207754.Peer-Reviewed Original ResearchImpact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis (P12-3.001)
Venkatesh S, Riley C, Dhand A, Doshi N, Kavak K, Levit E, Perrone C, Weinstock-Guttman B, Longbrake E, De Jager P, Xia Z. Impact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis (P12-3.001). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203369.Peer-Reviewed Original Research
2022
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Freeman L, Longbrake E, Coyle P, Hendin B, Vollmer T. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis. CNS Drugs 2022, 36: 1285-1299. PMID: 36350491, PMCID: PMC9645316, DOI: 10.1007/s40263-022-00965-7.Peer-Reviewed Original ResearchConceptsRelapsing-remitting multiple sclerosisHigh-efficacy therapiesMultiple sclerosisClinical benefitEarly treatmentRecent international consensus guidelinesLong-term clinical outcomesAvailable treatment optionsInternational consensus guidelinesTreatment-naïve individualsMechanism of actionDMT optionsMS careDisease courseClinical outcomesConsensus guidelinesTherapy optionsTreatment optionsNeurological damageTreatment strategiesEscalation approachClinical practiceUS FoodDrug AdministrationPatientsInfection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease
Peters J, Longbrake E. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Multiple Sclerosis And Related Disorders 2022, 68: 104400. PMID: 36544307, PMCID: PMC10075342, DOI: 10.1016/j.msard.2022.104400.Peer-Reviewed Original ResearchConceptsLong-term B-cell depletionB-cell depletionReal-world cohortSevere infectionsTotal infectionsSingle-center observational studyEffective disease-modifying therapiesInfectious adverse effectsFormer smoking statusRisk of hospitalizationAutoimmune neurologic diseasesAutoimmune neurologic disordersDisease-modifying therapiesYears of treatmentRate of infectionLong-term useImmunologic changesLaboratory abnormalitiesClinical factorsSmoking statusHigher BMIMultiple sclerosisSerious infectionsNeurologic disordersFemale genderImpaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosis
Asashima H, Axisa PP, Pham THG, Longbrake EE, Ruff WE, Lele N, Cohen I, Raddassi K, Sumida TS, Hafler DA. Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosis. Journal Of Clinical Investigation 2022, 132: e156254. PMID: 36250467, PMCID: PMC9566906, DOI: 10.1172/jci156254.Peer-Reviewed Original ResearchConceptsRelapsing-remitting multiple sclerosisMemory B cellsCTfh cellsB cellsTIGIT expressionMultiple sclerosisT cellsFollicular helper T cellsHealthy age-matched controlsB-cell depletionT cell expansionHelper T cellsAge-matched controlsB cell functionB-cell pathwayDifferential gene expression signaturesTfh cellsDisease activityGene expression signaturesCell depletionCD40 ligandTranscription factor TCF4Disease pathogenesisImmune systemNew MRIToward Precision Phenotyping of Multiple Sclerosis
Pitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PL, Wesley S, Boster A, Topalli I, Bagnato F, Mansoor M, Stuve O, Kister I, Pelletier D, Stathopoulos P, Dutta R, Lincoln MR. Toward Precision Phenotyping of Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation 2022, 9: e200025. PMID: 36041861, PMCID: PMC9427000, DOI: 10.1212/nxi.0000000000200025.Peer-Reviewed Original ResearchConceptsMultiple sclerosisSecondary progressive multiple sclerosisPathological processesProgressive multiple sclerosisKey pathological processClinical trial designDevelopment of biomarkersPerilesional inflammationNeuroaxonal degenerationMS phenotypeTrial designClinical importancePersonalized careM phenotypeSclerosisPhenotypeRemyelinationInflammationSyndromePrognosticationDegenerationProgressionBiomarkersCare